source
- Oruka Therapeutics reports Phase 2 psoriasis results with 63% of patients showing plaque improvementOruka Therapeutics announced results from its Phase 2 trial in moderate to severe plaque psoriasis. The study enrolled 63 patients and 40 of them, about 63.5%, achieved the predefined level of ski…
- AI-driven biotech Fathom Therapeutics secures $47 million Series A funding and rebrands from AtommapFathom Therapeutics, the company formerly known as Atommap, announced that it has closed a $47 million Series A financing round. The capital raise will support the firm’s effort to combine artifici…